Completed PHASE1 INTERVENTIONAL 1-arm NCT00788060

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma (Rad/Sutent)

A Single Arm, Phase Ib Study of RAD001 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Sponsor: Daniel George, MD

Interventions Everolimus (RAD001) Sunitinib (Sutent)

Updated 6 times since 2017 Last updated: Feb 12, 2015 Started: Oct 31, 2008 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00788060, this PHASE1 trial focuses on Renal Cell Carcinoma and remains completed. Sponsored by Daniel George, MD, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daniel George, MD
Novartis
Pfizer

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States